Product Description
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286478/)
Mechanisms of Action: IL12 Inhibitor
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Neumedicines Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Radiation Syndrome|Diffuse Large B-Cell Lymphoma|T-Cell Cutaneous Lymphoma|Injuries/wounds Unspecified|Mycosis Fungoides|Sezary Syndrome
Phase 1: Acute Radiation Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01742221 |
NCT01742221 | P1 |
Completed |
Acute Radiation Syndrome |
2012-11-01 |
2019-03-22 |
Treatments |
|
NCT02542124 |
TSEBT | P2 |
Unknown status |
Mycosis Fungoides|T-Cell Cutaneous Lymphoma|Sezary Syndrome |
2019-02-01 |
48% |
2020-11-04 |
|
NCT02544061 |
2015-SWI-004 | P2 |
Completed |
Injuries/wounds Unspecified |
2017-10-31 |
2025-08-27 |
||
NCT02544724 |
NM-ONC-002 | P2 |
Unknown status |
Diffuse Large B-Cell Lymphoma |
2017-08-01 |
2019-03-20 |
Treatments |
|
NCT02343133 |
#HHSO100201100037C | P2 |
Completed |
Acute Radiation Syndrome |
2016-04-01 |
2019-03-20 |
Treatments |